How Will the Biosimilar Market Change in 2018?


Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.

“Right now, I think we’re at 7 that have been approved by the FDA, with a couple more in the pipeline. I think, as of 2015, I believe IMS Health came out with something where there were 41 of these in development. So I know that there’s probably more coming on, and I think more will come on once we get some clarity from the FDA about what direction they’re going to do as far as regulating biosimilars, but I don’t think this a trend that’s going away anytime soon. At the end, we all want to lower prices, patients need to be taken care of by specialty pharmacies, and they realize that, and I know patients have become a lot more savvy about what’s out there. So, I think everybody’s really just trying to figure out how are biosimilars going to effect the market, and how much are they going to lower the price?”

Related Videos
Medical professional researching on a laptop while taking notes
Credit: Adobe Stock - Tierney
Yaruniv-Studio -
Technician- © pharmacytimes
Woman holding a rainbow heart for Pride Month | Image credit: Iuliia Pilipeichenko -
Related Content
© 2023 MJH Life Sciences

All rights reserved.